Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-Concept Study of LY2828360 for Osteoarthritic Knee Pain
2010-024320-23Phase 2Completed
- Sponsor
- Chorus Life Sciences
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) and chronic pain comparing LY2828360 with Placebo (2 arms). Primary endpoints: Safety and tolerability of LY2828360 80 mg once daily and Change from baseline in osteoarthritic knee pain severity (Average Pain Scores, APS). Started Feb 2011; status: completed.
02
Drugs
LY2828360
03
Conditions
knee osteoarthritis (OA)chronic pain
Beyond the preview
Go deeper on 2010-024320-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024320-23.